To elucidate the effects of cerebral venous sinus thrombosis (CVST) on mice and the effects of sarpogrelate (S) on CVST, mice were randomly divided into the sham-operated group, CVST group, and CVST + S group (sarpogrelate). Neurological function was evaluated using the rotarod test, balance beam test, and open-field test. Moreover, laser speckle contrast imaging was employed to observe the blood flow in the cerebral cortex of mice, and immunofluorescence was used to quantify the neurons. In the neurofunctional assessment tests (i.e., rotarod test, balance beam test, and open-field test), the CVST group exhibited poorer performance compared to the sham-operated group. However, mice treated with sarpogrelate showed significantly better performance than the CVST group (P < 0.05). Moreover, a significant decrease in cerebral blood flow was observed in the CVST group compared to the sham-operated group (P < 0.01). In contrast, a significant increase in blood flow was observed in the CVST + S group compared to the CVST group (P < 0.05). Furthermore, the number of neurons in the hippocampus and prefrontal cortex of mice in the CVST group was lower than that in the sham group (P < 0.05), and the number of neurons in the hippocampus and prefrontal cortex of the CVST + S group was higher than that of the CVST group (P < 0.05). Sarpogrelate can increase blood flow in the cerebral cortex of mice with CVST, leading to decreased neuronal cell damage and improved neurological function.